Irritable bowel syndrome gains new treatment

Amitiza has gained a new indication-to treat irritable bowel syndrome with constipation in women.

Amitiza (lubiprostone), formerly approved to treat chronic idiopathic constipation, has gained clearance for a new indication. The drug can now be used to treat irritable bowel syndrome with constipation (IBS-C) in adult women. According to Sucampo Pharmaceuticals and Takeda Pharmaceuticals America, the product is the only approved treatment for IBS-C in this country.